Trial design for mold-active agents: Time to break the mold - Aspergillosis in neutropenic adults

Clinical Infectious Diseases

Volumn 44, Issue 10, 2007, Pages 1298-1306

  Anaissie, Elias J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ASPERGILLOSIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPOKALEMIA; IMMUNITY; INCIDENCE; MOULD; NEPHROTOXICITY; NEUTROPENIA; NOTE; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 34248141777     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514352     Document Type: Note

References (86)

1. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
2. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007; 44:1289-97 (in this issue).
3. Willman D. A Times investigation: drug trials with a dose of doubt. A National Institutes of Health researcher with ties to pharmaceutical firms helped test their new medications: some scientists questioned the results of the studies. Los Angeles Times 2006:A1.
4. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764-71.
5. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391-402.
6. Anaissie EJ, Segal BH, Graybill JR, et al. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis 2006; 43:1031-9.
7. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
8. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis 2006; 43:1449-55.
9. Powers JH. Salvage therapy trials in invasive fungal disease: challenges and opportunities. Clin Infect Dis 2006; 43:1456-60.
10. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12.
11. Anaissie EJ, Mattiuzzi GN, Miller CB, et al. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 1998; 42:606-11.
12. Miceli MH, Maertens J, Buvé K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer (in press).
13. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173: 707-17.
14. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-8.
15. Woods G, Miceli M, Grazziutti M, et al. Validation of serum aspergillus galactomannan index as a surrogate endpoint for outcome of invasive aspergillosis: clinical and research implications [abstract 2861]. Blood 2006; 108: 2861.
16. Steinbach WJ, Loeffler J, Stevens D. Aspergillosis. In: Wingard JR, Anaissie E, eds. Fungal infections in the immunocompromised patient. Boca Raton, FL: Taylor & Francis Group, 2005:257-94.
17. Greene R. Radiology of fungal infections in the immunocompromised patient. In: Wingard JR, Anaissie E, eds. Fungal infections in the immunocompromised patient. 1st ed. Vol. 1. Boca Raton, FL: Taylor & Francis Group, 2005:407-29.
18. Grazziutti ML, Dong L, Miceli MH, et al. Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients. Bone Marrow Transplant 2006; 37:403-9.
19. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53:337-49.
20. Sharma S, Nadrous HF, Peters SG, et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005; 128:1385-92.
21. Subira M, Martino R, Rovira M, Vazquez L, Serrano D, De La Camara R. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003; 82:80-2.
22. Hachem R, Sumoza D, Hanna H, Girgawy E, Munsell M, Raad I. Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised? Cancer 2006; 106:1581-6.
23. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97:135-44.
24. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45:3487-96.
25. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35:359-66.
26. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563-71.
27. Miceli M, Grazziutti M, Woods G, et al. Outcome of invasive aspergillosis in patients with hematological cancer: immunity is (almost) everything [abstract 5314]. Blood 2006; 108: 5314.
28. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
29. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47.
30. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-50.
31. Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126:852-60.
32. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42:2733-41.
33. Pazos C, Ponton J, Del Palacio A. Contribution of (1→3)-beta-D- glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43:299-305.
34. Sulahian A, Boutboul F, Ribaud P, Leblanc T, Lacroix C, Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001; 91:311-8.
35. Gottlieb S. Remarks on adaptive trial design. In: Program and abstracts of the 2006 Conference on Adaptive Trial Design (Washington, DC). US Food and Drug Administration. 10 July 2006. Available at: http://www.fda.gov/ oc/speeches/2006/trialdesign0710.html. Accessed 1 February 2007.
36. US Food and Drug Administration. Innovation or stagnation? challenge and opportunity on the critical path to new medical products. 16 March 2004. Available at: http://www.fda .govoc/initiatives/criticalpath/whitepaper .html. Accessed 2 February 2007.
37. Woodcock J. Biomarkers: physiological & laboratory markers of drug effect. 26 October 2006. Available at: http://clinicalcenter.nih .gov/researchers/training/principles/ppt/ Physiological_Laboratory_Markers_of_Drug_Effect _2005-2006.ppt. Accessed 2 February 2007.
38. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004; 1:189-95.
39. Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 2006; 8:128-39.
40. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834-43.
41. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46:1857-69.
42. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46:12-23.
43. Petriatis V, Tetriatiene R, Hope W, et al. Combination therapy of voriconazole and anidulafungin improves outcome of experimental pulmonary aspergillosis [abstract M-882]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society for Microbiology, 2006.
44. van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg IA. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57:732-40.
45. Sionov E, Mendlovic S, Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 2006; 53: 131-9.
46. Sionov E, Mendlovic S, Segal E. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 2005; 56:594-7.
47. Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994; 169:356-68.
48. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188:305-19.
49. Salonen J, Lehtonen OP, Terasjarvi MR, Nikoskelainen J. Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scand J Infect Dis 2000; 32:485-90.
50. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J 1996; 15: 232-7.
51. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003; 41:2184-6.
52. Pazos C, del Palacio A. Early diagnosis of invasive aspergillosis in neutropenic patients with bi-weekly serial screening of circulating galactomannan by Platelia Aspergillus [in Spanish]. Rev Iberoam Micol 2003; 20:99-102.
53. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97:1604-10.
54. Lombardi G, Farina C, Andreoni S, et al. Multicenter evaluation of an enzyme immunoassay (Platelia Aspergillus) for the detection of Aspergillus antigen in serum. Mycopathologia 2002; 155:129-33.
55. Bretagne S, Marmorat-Khuong A, Kuentz M, Latge JP, Bart-Delabesse E, Cordonnier C. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect 1997; 35:7-15.
56. Bretagne S, Costa JM, Bart-Delabesse E, Dhedin N, Rieux C, Cordonnier C. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998; 26:1407-12.
57. Maertens J, Glasmacher A, Selleslag D, et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41:e9-14.
58. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34:939-43.
59. Petraitiene R, Petraitis V, Lyman CA, et al. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2004; 48: 1188-96.
60. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45:857-69.
61. Petraitis V, Petraitiene R, Solomon J, et al. Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50:1510-7.
62. Miceli MH, Anaissie E. When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all. Clin Infect Dis 2007; 44:757-60.
63. Garcia ME, Caballero J, Cruzado M, Andrino M, Gonzalez-Cabo JF, Blanco JL. The value of the determination of anti-Aspergillus IgG in the serodiagnosis of canine aspergillosis: comparison with galactomannan detection. J Vet Med B Infect Dis Vet Public Health 2001; 48: 743-50.
64. Wasan KM, Sivak O, Rosland M, Risovic V, Bartlett K. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet(R) and AmBisome(R) in combination with caspofungin to rats infected with Aspergillus fumigatus. J Pharm Sci 2006 [Epub ahead of print].
65. Rovira M, Jimenez M, De La Bellacasa JP, et al. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 2004; 77:1260-4.
66. Verdaguer V, Walsh TJ, Hope W, Cortez KJ. Galactomannan antigen detection in the diagnosis of invasive aspergillosis. Expert Rev Mol Diagn 2007; 7:21-32.
67. Ulusakarya A, Chachaty E, Vantelon JM, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000; 1:111-6.
68. Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40:1496-9.
69. Chmura Kraemer H, Periyakoil VS, Noda A. Kappa coefficients in medical research. Stat Med 2002; 21:2109-29.
70. Tabone MD, Vu-Thien H, Latge JP, et al. Value of galactomannan detection by sandwich enzyme-linked immunosorbent assay in the early diagnosis and follow-up of invasive aspergillosis. Opportunistic Pathogens 1997; 9: 7-13.
71. Verweij PE, Dompeling EC, Donnelly JP, Schattenberg AV, Meis JF. Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis: preliminary investigations with two examples. Infection 1997; 25: 86-9.
72. Nourry L, Gagnadoux F, Pierrot M, Gourdier AL, Mercat A, Racineux JL. Invasive pulmonary aspergillosis complicating septic shock [in French]. Rev Mal Respir 2005; 22:806-10.
73. Moragues MD, Amutio E, Garcia-Ruiz JC, Ponton J. Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis [in Spanish]. Rev Iberoam Micol 2003; 20: 103-10.
74. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190:641-9.
75. Machida U, Kami M, Kanda Y, et al. Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24:1145-9.
76. Machetti M, Zotti M, Veroni L, et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000; 2:140-4.
77. Machetti M, Feasi M, Mordini N, et al. Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant 1998; 21:917-21.
78. Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33: 1504-12.
79. Jarque I, Andreu R, Salavert M, et al. Value of Aspergillus galactomannan antigen detection in the diagnosis and follow-up of invasive aspergillosis in hematological patients [in Spanish]. Rev Iberoam Micol 2003; 20:116-8.
80. Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer 2006; 48:28-34.
81. El Saleeby CM, Allison KJ, Knapp KM, Walsh TJ, Hayden RT. Discordant rise in galactomannan antigenemia in a patient with resolving aspergillosis, renal failure, and ongoing hemodialysis. J Clin Microbiol 2005; 43:3560-3.
82. Centeno-Lima S, de Lacerda JM, do Carmo JA, Abecasis M, Casimiro C, Exposto F. Follow-up of anti-Aspergillus IgG and IgA antibodies in bone marrow transplanted patients with invasive aspergillosis. J Clin Lab Anal 2002; 16:156-62.
83. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121:448-57.
84. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007; 356:409-11.
85. Wingard JR, Anaissie E. Treatment of Invasive fungal infections. In: Wingard JR, Anaissie E, eds. Fungal infections in the immunocompromised patient. 1st ed. Vol. 1. Boca Raton, FL: Taylor & Francis Group, 2005:642-66.
86. Dennis CG, Greco WR, Brun Y, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006; 50:422-7.